about
Safety evaluation of ruxolitinib for treating myelofibrosis.The role of the JAK-STAT pathway in neural stem cells, neural progenitor cells and reactive astrocytes after spinal cord injuryUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingTwo faces of inflammation: an immunopharmacological view.Versican G1 domain enhances adenoviral-mediated transgene expression and can be modulated by inhibitors of the Janus kinase (JAK)/STAT and Src family kinase pathways.The JAK/STAT pathway in obesity and diabetes.Oxidative stress in psoriasis and potential therapeutic use of antioxidants.Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.Challenges to develop novel anti-inflammatory and analgesic drugs.Arctigenin promotes apoptosis in ovarian cancer cells via the iNOS/NO/STAT3/survivin signalling.Negative Regulators of JAK/STAT Signaling in Rheumatoid Arthritis and Osteoarthritis.RNA sequencing reveals resistance of TLR4 ligand-activated microglial cells to inflammation mediated by the selective jumonji H3K27 demethylase inhibitorMicroarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.Osteopontin production by TM4SF4 signaling drives a positive feedback autocrine loop with the STAT3 pathway to maintain cancer stem cell-like properties in lung cancer cells.The role of STAT3 in leading the crosstalk between human cancers and the immune system.Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment.MicroRNA hsa-miR-324-5p Suppresses H5N1 Virus Replication by Targeting the Viral PB1 and Host CUEDC2
P2860
Q33415731-19EC7D2B-75A0-4218-BC29-B305F132BA12Q35180002-F627F482-E15E-46A3-912C-C73B619D15F8Q35822379-D4EF0FA6-1F67-4984-9287-AF74C3E808C1Q38167040-1BD38522-829C-4987-8366-C59007B5B68BQ38690392-E3F3F787-A1D2-4744-A3F8-4C364F2F1DFFQ38773189-F6990A4F-1287-45BC-8CF6-D126139D79C9Q38813221-376026BA-EB29-4C11-9F2C-090B3E864D12Q38925157-E85DB5A0-34C0-4DD7-BFC1-C4448DC3C1F5Q38941483-0A70F082-7A3F-4AEB-82EA-DC231D77B8D9Q38993553-EBEF5A96-82EC-4323-A2CE-36E69A8CB0CBQ39154718-7CCB7037-E6C4-4472-B169-BD825641A095Q41140252-2C4D3232-B005-4C6B-B8FD-A18D0B819DE5Q41366654-D36BDA8E-AAA8-4E78-A896-7F36AC42116FQ47144510-AC8271BA-EF8D-4A39-91DB-F023A1B3FE92Q49990319-C2F24910-C781-430C-B1DA-36410EDA776FQ55008538-D15E0B8B-2E94-459C-BA81-7537ED521C38Q57093661-39FCDA00-7DF2-4F6C-A974-7D4E66A57545
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Therapeutic targeting of the Jak/STAT pathway.
@en
type
label
Therapeutic targeting of the Jak/STAT pathway.
@en
prefLabel
Therapeutic targeting of the Jak/STAT pathway.
@en
P2860
P356
P1476
Therapeutic targeting of the Jak/STAT pathway
@en
P2093
Saara Aittomäki
P2860
P356
10.1111/BCPT.12164
P50
P577
2013-11-15T00:00:00Z